Complementary traditional Chinese medicine therapy improves survival in patients with metastatic prostate cancer

Medicine (United States)

Volumn 95, Issue 31, 2016, Pages

  Liu, Jui Ming ^a   Lin, Po Hung ^b,c   Hsu, Ren Jun ^d,e,f   Chang, Ying Hsu ^b   Cheng, Kuan Chen ^g,h   Pang, See Tong ^b   Lin, Shun Ku ⁱ  

^a TAO YUAN GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d Biobank Management Center of the Tri Service General Hospital   (China)

^e Division of Hematology and Oncology Department of Medicine Tri Service General Hospital   (China)

^f Graduate Institute of Life Sciences   (China)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

androgen deprivation therapy; complementary therapies; National Health Insurance Research Database; prostate cancer; traditional Chinese medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CHINESE DRUG; HACHIMIJIOGAN; HERBACEOUS AGENT;

ACUPUNCTURE; ADULT; ADVANCED CANCER; AGED; ALTERNATIVE MEDICINE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHARLSON COMORBIDITY INDEX; CHINESE MEDICINE; COHORT ANALYSIS; FOLLOW UP; HEALTH INSURANCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASSAGE; METASTASIS; MIDDLE AGED; MORTALITY RATE; MORTALITY RISK; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; AGE; COMORBIDITY; FACTUAL DATABASE; HYPERTENSION; INSURANCE; LIVER CIRRHOSIS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; STATISTICAL MODEL; TAIWAN;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INSURANCE COVERAGE; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 84983335822     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004475     Document Type: Article

References (37)

1. Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet 2016; 387:70-82.
2. Department of Health, the Executive Yuan, Republic of China. Cancer Registry Annual Report 2000-2012, Taiwan; 2013. Available from: http://www. hpa. gov. tw/Bhpnet/Web/Stat/StatisticsShow. aspx?No=200 911300001. Accessed July 1, 2016.
3. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177: 2106-31.
4. Ministry of Health and Welfare. 2012 Statistics of causes of death in Taiwan. Available from: http://www. mohw. gov. tw/EN/Ministry/Statis tic-P. aspx?f-list-no=474&fod-list-no=5016&doc-no=45358. Accessed December 1, 2015.
5. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000;88:615-9.
6. Lin YH, Chen KK, Chiu JH. Use of Chinese medicine among prostate cancer patients in Taiwan: a retrospective longitudinal cohort study. Int J Urol 2011;18:383-6.
7. Philippou Y, Hadjipavlou M, Khan S, et al. Complementary and alternative medicine (CAM) in prostate and bladder cancer. BJU Int 2013;112:1073-9.
8. Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 2015;175:1527-9.
9. National Health Research Institutes. National Health Insurance Research Database (online). Available from: http://nhird. nhri. org. tw/date-01. htm. Accessed October 1, 2015.
10. Lee YW, Chen TL, Shih YR, et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer 2014;120:1338-44.
11. Lee CW, Muo CH, Liang JA, et al. Association of intensive morphine treatment and increased stroke incidence in prostate cancer patients: a population-based nested case-control study. Jpn J Clin Oncol 2013; 43:776-81.
12. Chamie K, Daskivich TJ, Kwan L, et al. Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med 2012;27:492-9.
13. Sun LM, Lin MC, Lin CL, et al. Statin use reduces prostate cancer allcause mortality: a nationwide population-based cohort study. Medicine (Baltimore) 2015;94:e1644.
14. Yoshida Y, Wang MQ, Liu JN, et al. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol 1997;19:359-70.
15. Ravipati AS, Zhang L, Koyyalamudi SR, et al. Antioxidant and antiinflammatory activities of selected Chinese medicinal plants and their relation with antioxidant content. BMC Complement Altern Med 2012;12:173-6.
16. Yang Y, Chin A, Zhang L, et al. The role of traditional Chinese medicines in osteogenesis and angiogenesis. Phytother Res 2014;28:1-8.
17. Zheng KY, Choi RC, Cheung AW, et al. Flavonoids from Radix Astragali induce the expression of erythropoietin in cultured cells: a signaling mediated via the accumulation of hypoxia-inducible factor-1a. J Agric Food Chem 2011;59:1697-704.
18. Huang XP, Tan H, Chen BY, et al. Astragalus extract alleviates nerve injury after cerebral ischemia by improving energy metabolism and inhibiting apoptosis. Biol Pharm Bull 2012;35:449-54.
19. Tsujimura A, Takada S, Matsuoka Y, et al. Clinical trial of treatment with saikokaryukotsuboreito for eugonadal patients with late-inset hypogonadism-related symptoms. Aging Male 2008;11:95-9.
20. HaKT,KimJK,Kang SK, et al. Inhibitory effect of Sihoga-Yonggol-Moryo-Tang on matrix metalloproteinase-2 and-9 activities and invasiveness potential of hepatocellular carcinoma. Pharmacol Res 2004;50:279-85.
21. Still K, Robson CN, Autzen P, et al. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25.
22. Schwarz RE, Donohue CA, Sadava D, et al. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett 2003;189:59-68.
23. Chan FL, Choi HL, Chen ZY, et al. Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin. Cancer Lett 2000;160:219-28.
24. Matsuzaki Y, KurokawaN, Terai S, et al. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res 1996;87:170-7.
25. Yao M, Yang J, Cao L, et al. Saikosaponin-d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase. Mol Med Rep 2014;10:365-72.
26. Saha A, Blando J, Silver E, et al. 6-Shogaol from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo through inhibition of STAT3 and NF-(B signaling. Cancer Prev Res (Phila) 2014;7:627-38.
27. Yagi H, Sato R, Nishio K, et al. Clinical efficacy and tolerability of two Japanese traditional herbal medicines, Hachimi-jio-gan and Gosha-jinkigan, for lower urinary tract symptoms with cold sensitivity. JTCM 2015;5:258-61.
28. Chen H, Wu M, Kubo KY. Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats. J Ethnopharmacol 2012;142:80-5.
29. Ogirima T, Tano K, Kanehara M, et al. Effects of the Chinese herbal medicine based on Hachimi-jio-gan in male rats with the adenineinduced osteopenia. J Tradit Chin Med 2005;25:226-32.
30. Usuki S. Hachimijiogan changes serum hormonal circumstance and improves spermatogenesis in oligozoospermic men. Am J Chin Med 1986;14:37-45.
31. Utsugi T, Igarashi M, Yazaki C, et al. Effects of Hachimijiogan on hypothalamo-pituitary-testicular system. Nihon Sanka Fujinka Gakkai Zasshi 1983;35:2305-10.
32. Aggarwal BB. Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 2008;7:1436-40.
33. Gururaj AE, BelakavadiM, Venkatesh DA, et al. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002;297:934-42.
34. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-30.
35. Hour TC, Chen J, Huang CY, et al. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIPI and C/EBP expressions and suppressing NF-kB activation. Prostate 2002;51:211-8.
36. Department of Health, the Executive Yuan, Republic of China. Cancer Registry Annual Report 2000-2012, Taiwan; 2013. Available from: http://www. hpa. gov. tw/Bhpnet/Web/Stat/StatisticsShow. aspx?No= 200911300001. Accessed July 1, 2016.
37. National Cancer Institute. PSA values and SEER data: SEER data, 1973-2012 (November 2014 submission). Available from: http://seer. cancer. gov/data/psa-values. html. Accessed July 1, 2016.